Semin Respir Crit Care Med 2000; 21(3): 245-262
DOI: 10.1055/s-2000-9855
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 760-0888

Advances in Infection Control: Ventilator-Associated Pneumonia

Mohammed H. Hijazi, M.B.B.Ch. and Neil R. MacIntyre
  • Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, North Carolina
Further Information

Publication History

Publication Date:
03 March 2004 (online)

ABSTRACT

Mechanically ventilated patients are 6-21 times more likely to develop nosocomial pneumonia. It is estimated that between 6% and 52% of ventilated patients develop ventilator-associated pneumonia (VAP) with attributable mortality of 27-51%. Certain high risk organisms carry higher mortality (e.g., Pseudomonas aeruginosa and Acinetobacter spp.). Aspiration of colonized orodigestive secretions is the commonly recognized route of infection, whereas inhalation of contaminated aerosol hematogenous spread and direct infection are less common. Gram-negative pathogens are responsible for 40-60% of VAP, whereas gram-positive pathogens cause 15-20%, and it is commonly polymicrobial. Diagnosis remains difficult, and studies showed that early appropriate treatment can improve patient outcome. Better understanding of the pathogenesis and risk factors is important for implementing more effective infection control measures. Clinical trials evaluating outcome will help in assessing current and future preventive and therapeutic measures.

    >